-
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例:华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势,细胞生物临床研究不断深化,伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成,生态圈的完善将在很大限度上推动产业快速发展。数据显示,中国细胞治疗企业融资金额不断增加,从2014年的0.2亿元增长至2019年的28.9亿元。其中,2018年中国细胞治疗企业融资额同比增长706.8%,呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇,同时也有挑战并存。后续产业的发展,将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局,企业也应积极开展生态合作以及更为密切关注市场需求动向,将疗法和新一代医疗创新技术深度融合,实现市场产品多元化与差异化,并推出独特性的精准治疗,从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告 |2019中国茶行业市场大数据及标杆商业模式研究报告
本报告研究涉及企业/品牌/案例:小罐茶,大益茶,艺福堂,小马茶业,喜茶,二奈雪の茶,益禾堂,19tea,一芳台湾水果茶,鹿角巷the Ally,一点点,一些柠檬一些茶,四云奶盖贡茶,Taning挞柠•匠心柠檬茶,答案茶,丧茶,快乐柠檬,茶の井,CoCo都可,大卡司,吴裕泰茶业,黄山王光熙松萝茶业股份公司,天府(開曼)控股有限公司,四川省峨眉山竹叶青茶业有限公司,武夷星茶业有限公司,勐海陈升茶业有限公司,咸阳泾渭茯茶有限公司,湖南华莱生物科技有限公司
2019年,中国茶叶产量产值不断上涨,出口量出口额不断增加,内销量与内销额也不断提高,茶行业未来发展前景具有巨大的潜力。中国茶行业已形成全产业链,同时形成了具有规模的线上茶叶市场,截至2019年,中国茶叶线上市场规模达到235.0亿元。中国茶叶经典品牌小罐茶,整合上游茶园资源,并重视技术革新,建立智能化工厂,形成大规模的茶园和生产加工厂,于2019年收获了4.0亿元人民币的融资资本。另外,中国茶叶后市场兴起,带动了年轻一代消费者对茶叶的消费的热情,如新式茶饮品牌喜茶,用创新的产品设计、良好的定价策略以及精准的市场定位,成功开拓出新式茶饮的市场,收获4.0亿元的融资,完成布局31个地区。
In 2019, the output value of China's tea production continued to rise, the export volume of exports continued to increase, and the volume of domestic sales and domestic sales continued to increase. The future development prospects of the tea industry have great potential. The Chinese tea industry has formed a full industrial chain, and at the same time formed a large-scale online tea market. By 2019, the Chinese tea online market reached 23.5 billion yuan. China's tea classic brand XIAO GUAN TEA, integrated upstream tea garden resources, and attached importance to technological innovation, the establishment of intelligent factories, the formation of large-scale tea gardens and production processing plants, harvested 400 million yuan of financing capital in 2019. In addition, the rise of the Chinese tea market has spurred the enthusiasm of the younger generation of consumers for tea consumption, such as the new tea HEYTEA, with innovative product design, good pricing strategy and precise market positioning, successfully developed new tea. The market for drinking, harvesting 400 million yuan of financing, completed the layout of 31 regions. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告